Press release
PREMIER Biosoft International releases AlleleID version 7.01 offering enhanced support for custom MLPA® probe design
Palo Alto, California – March 5, 2009 PREMIER Biosoft International today announced the world wide release of AlleleID version 7.01. AlleleID, the suite for qPCR and microarrays, now includes support for the latest design guidelines laid down by MRC-Holland, the inventors of the technology. MLPA® is an easy-to-use molecular biology technique which has been gaining attention especially for studies of DNA copy number changes.With this release, AlleleID now also supports the UCSC genome browser file format, developed and maintained by the Genome Bioinformatics Group, University of California at Santa Cruz. AlleleID 7.01 includes a greatly enhanced automatic homology avoidance algorithm that enables users to design assays with greater specificity, avoiding unrelated SNPs at the same time.
For details, please visit: http://www.premierbiosoft.com/bacterial-identification/realtime-PCR/mlpa.html
About PREMIER Biosoft International:
Founded in 1994, the company is a group of computer scientists and molecular biologists dedicated to producing cutting-edge intuitive software for the molecular biologist. The goal of the company is to study the most recent innovations in molecular biology and translate them into software products that aid biologists. Additional information about PREMIER Biosoft International is available at http://www.PremierBiosoft.com.
About MRC-Holland
MRC-Holland published its first article about MLPA® technology in 2002 and since then, its product range has grown explosively. The company now offers well over a 200 different MLPA® tests for a wide range of applications, from rare genetic diseases to tumor analysis. MRC-Holland aims to make the MLPA® technology available to all scientists and works in close collaboration with researchers around the world. More information about MRC-Holland can be found on www.MLPA.com.
Contact:
Arun Apte
PREMIER Biosoft International
650-856-2703
http://www.PremierBiosoft.com
PREMIER Biosoft is a leading software solutions company and author exclusively for molecular biologists. Our software have been used and appreciated by researchers worldwide and have been often cited as well.
PREMIER Biosoft International
3786 Corina Way
Palo Alto, CA 94303-4504
Fax: 650-618-1773
Phone: 888-847-7494
Email: support@premierbiosoft.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release PREMIER Biosoft International releases AlleleID version 7.01 offering enhanced support for custom MLPA® probe design here
News-ID: 70860 • Views: …
More Releases for MLPA
Emerging Trends to Drive Neurogenetic Testing Market Growth at 13.5% CAGR Throug …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Neurogenetic Testing Market Size Growth Forecast: What to Expect by 2025?
Recently, there has been a swift development in the neurogenetic testing market size. The market is set to expand from $0.61 billion in 2024 to $0.7 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 13.9%.…
Neurogenetic Testing Market Anticipated To Witness Robust Growth, Surpassing $1. …
The Neurogenetic Testing Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Current Neurogenetic Testing Market Size and Its Estimated Growth Rate?
The neurogenetic testing market has seen fast growth. It will grow from $0.61 billion in 2024 to $0.7 billion in 2025 at…
Rising Prevalence Of Neurological Disorders Fuels Demand For Neurogenetic Testin …
Which drivers are expected to have the greatest impact on the over the neurogenetic testing market's growth?
The increasing prevalence of neurological disorders is also expected to propel the growth of the neurogenetic testing market. These disorders affect the nervous system and can arise from genetic factors, infections, trauma, or degeneration. Neurogenetic testing offers valuable insights into the genetic risk factors of these conditions, guiding treatment choices and improving patient care.…
Neurogenetic Testing Market Poised for 13.5 % Growth, Set to Hit $21 Billion by …
How Is the Neurogenetic Testing Market Projected to Grow, and What Is Its Market Size?
The market size for neurogenetic testing has expanded considerably in the last few years. Its expansion will continue, with an increase from $0.61 billion in 2024 to $0.7 billion in 2025, reflecting a compound annual growth rate (CAGR) of 13.9%. Factors contributing to the growth during the historic period include a surge in neurological disease…
Global Neurogenetic Testing Market Impacting Factor's Research Report 2022- MRI, …
The Neurogenetic Testing Market is expected to grow at a stupendous rate in the next 10 years. The healthcare industry is being driven by innovation. The very idea of "Customer is the King" is being implemented. As such, healthcare IT solutions come across as a meticulous and complex system that constitutes interconnected and large-scale systems wherein micros are being worked upon. These would be the facets of the healthcare vertical…
PREMIER Biosoft and PamGene International B.V. form an alliance
Palo Alto, California—February 15th 2007. PREMIER Biosoft International, a leading bioinformatics company, and PamGene International B.V., owner of patented technologies for second-generation microarray products, have come together to develop a software tool to design custom oligos for use in MLPA® based assays.
Multiplex Ligation-dependent Probe Amplification (MLPA®) is a method for assessing tens to hundreds of gene copy number changes, single-nucleotide polymorphisms (SNPs), insertions and deletions and methylation markers in genomic…
